Deal Sheet

Representative
Transaction
Experience.

Strategic operator with a background in health economics and high-stakes diplomatic negotiation. Track record of bridging valuation gaps, structuring complex IP licensing, and securing capital for life sciences organizations.

$40B+

M&A Value

$3B+

Licensing

$6B+

Capital Formation

$2B+

Sovereign Finance

Category 01

M&A and Strategic Consolidation

Economist and part of negotiation team on buy-side and sell-side transactions ranging from $1B to $40B+.

$20B+

Acquisition (Buy-Side)

  • Led the pre-close integration workstream to identify divestiture risks, enabling the deal to clear regulatory hurdles without significant delay.
  • Structured a high-premium all-cash offer to preempt a competitive bidding war.
$5B

Immunology Acquisition (Buy-Side)

  • Helped negotiate an all-cash transaction that priced in probability of success, avoiding complex CVRs to ensure swift board alignment and deal certainty.
$10B+

Neuroscience Acquisition (Buy-Side)

  • Led commercial due diligence to validate the "launch curve" and market uptake model, giving the Investment Committee confidence to approve a >50% premium.
Defense

Merger & Defense Against Activist Campaign (Sell-Side)

  • Negotiated the definitive agreement to increase the exchange ratio and added a revenue-based CVR tied to commercial performance of an unapproved diagnostic asset.
  • Bridged the gap between the Buyer's conservative forecast and the Activist's bullish view, securing the vote.
Category 02

Strategic Licensing & Cross-Border Partnerships

$1B+

Drug Discovery Collaboration (Buy-Side)

  • Bridged the gap with a heavily back-loaded structure, aligning incentives strictly on clinical success rather than platform promise.
$3B+

Licensing Deal with Co-Commercialization (Buy-Side)

  • Negotiated a hybrid structure: significant upfront capital with tiered royalties and a co-commercialization option in select territories to satisfy the seller's desire for operational involvement.
Cross-Border

China-to-US Cross-Border License (Buy-Side)

  • Designed a governance structure with specific IP safeguards and data-transfer protocols that satisfied regulatory requirements in both jurisdictions.
Category 03

Corporate Strategy & Capital Formation

VBC

Value-Based Care Acquisition (Buy-Side)

  • Modeled the "cost-avoidance" synergy of diverting patients from ERs to owned clinics, justifying the valuation to the Board.
Spin-Off

Consumer Health Division (Strategy Advisor)

  • Shaped the Transition Services Agreement ensuring the new entity had IT/HR support for 18 months, ensuring a stable IPO.
$2.9B

Divestiture of Non-Core Assets (Sell-Side)

  • Bundled the package to include both commercial products and associated sales force, framing it as a "turnkey business unit" rather than just a bag of assets.
$1B

Monetization of Royalty Stream

  • Structured a "synthetic royalty" sale. The company sold a majority of its future royalty stream for a lump sum upfront, retaining a cap structure where rights revert after the investor achieves a specific IRR.
$2B

Strategic Development Financing & Royalty Purchase

  • As an economist, helped negotiate a development financing agreement where an investor paid 100% of trial costs in exchange for a fixed royalty on future sales, keeping the R&D expense off the company's P&L.
Category 04

Sovereign & Development Finance

$500M

Emergency Pandemic Response Facility

  • Negotiated an accelerated disbursement mechanism with Ministries of Finance, bypassing standard procurement bottlenecks to release funds in <14 days.
  • Established a "logistics corridor" coordination cell to secure medical supply chains.
$1.2B

Energy Infrastructure PPP

  • Structured a Partial Risk Guarantee where the World Bank backstopped the sovereign's payment obligations.
  • This "credit enhancement" layered public capital to de-risk private capital.
$450M

Health Sector Fiscal Reform & Budget Support

  • Designed a Performance-Based Financing framework. Tranches of capital were released only upon independent verification of specific health outcomes, aligning fiscal discipline with clinical metrics.
Global R&D

Product Development Partnership

  • Structured a catalytic funding mechanism that de-risked the "valley of death" between discovery and clinical trials.
  • Implemented a strict governance framework requiring harmonization of clinical trial standards across US, EU, and Sub-Saharan Africa.

Ready to talk?

Every engagement starts with a conversation. For a comprehensive view of transaction experience, book a confidential conversation.

Book a call